Aprea Therapeutics APRE 深 滬
已收盤 02-06 16:00:00 美东时间
0.69
+0.066
+10.51%
華盛通- 最 高0.69
- 今 開0.6149
- 成交量 52.57万股
- 最 低 0.5862
- 昨 收 0.6244
- 總市值 482.57万
- 52周最高 3.715
- 市盈率 靜 --
- 換手率 7.52%
- 52周最低 0.548
- 委 比 90.13%
- 總股本 699.38万
- 歷史最高 1062.20
- 量 比 0.02
- 振 幅 16.62%
- 歷史最低 0.548
- 每 手 1
- 風險率 0.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aprea Therapeutics CFO John P. Hamill Acquires Common Shares
Aprea Therapeutics CFO John P. Hamill Acquires Common Shares John P. Hamill, Senior Vice President, Chief Financial Officer, and Principal Financial and Accounting Officer of Aprea Therapeutics Inc., has reported the acquisition of common shares of the company. The full filing can be accessed throug
02-03 05:06
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Vyome Holdings (NASDAQ:HIND) stock increased by 16.1% to $2.23 during ...
02-02 20:05
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer
BUZZ-U.S. STOCKS ON THE MOVE-Church & Dwight, Tesla, Oppenheimer Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks fell on Friday after President Donald Trump nominated for
01-31 02:38
美股大行评级 | Meta 、IBM、拉姆研究、布林克国际等获多家机构上调目标价；微软、特斯拉、ServiceNow、自动数据处理等遭多家下调评级
今日重点评级关注：Piper Sandler：上调Korro Bio评级至"超配"，目标价从11美元升至30美元；Piper Sandler：维持Nurix Therapeutics"超配"评级，目标价从32美元升至35美元
01-30 17:38
Aprea Therapeutics prices $5.6M private placement
Aprea Therapeutics (NASDAQ: APRE) said on Thursday that it has entered into a securities purchase agreement with new and existing healthcare-focused institutional investors, as well as certain insider...
01-29 21:52
Aprea Therapeutics Reports Early Proof-of-Concept for WEE1 Inhibitor APR-1051 in Solid Tumors
Aprea Therapeutics Reports Early Proof-of-Concept for WEE1 Inhibitor APR-1051 in Solid Tumors Aprea Therapeutics Inc. announced early clinical proof-of-concept results from its ongoing Phase 1 ACESOT-1051 dose-escalation trial evaluating the WEE1 inhibitor APR-1051 in patients with advanced solid tu
01-29 21:27
Aprea Therapeutics Commences ~$5.6M Offering Of 6.289M Common Shares, Warrants At $0.89 Apiece
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage
01-29 21:26
Aprea Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price
Aprea Therapeutics Faces Nasdaq Delisting Risk Over Minimum Bid Price Aprea Therapeutics Inc. has received a deficiency letter from the Nasdaq Listing Qualifications Department, notifying the company that its common stock has traded below the minimum required bid price of $1.00 per share for 30 cons
01-26 15:49
Aprea Therapeutics Updates Oncology Pipeline and Strategy Outlook
Aprea Therapeutics ( ($APRE) ) has issued an update. On January 9, 2026, Aprea ...
01-10 06:09
Aprea Therapeutics Updates 2025 Progress, Cash Runway To Support Operations Through Q1 2027
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that target weaknesses in cancer cells while minimizing damage to healthy
2025-12-18 21:39
